Current experience with 5-HT3 receptor antagonists in fibromyalgia (Q34139435)

31 July 2017

1 reference

title

Current experience with 5-HT3 receptor antagonists in fibromyalgia (English)

1 reference

31 July 2017

0 references

Michael Späth

1

1 reference

31 July 2017

publication date

1 May 2002

1 reference

Rheumatic Diseases Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

28

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

319-328

1 reference

Advances in fibromyalgia: possible role for central neurochemicals

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Neurohormonal perturbations in fibromyalgia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Neurobiological concepts of fibromyalgia--the possible role of descending spinal tracts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Learning and memory in pain pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

5-HT receptor classification and nomenclature: towards a harmonization with the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Identification and distribution of 5-HT3 recognition sites in the rat gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Nervous system distribution of the serotonin 5-HT3 receptor mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Spinal 5-HT3 receptor-mediated antinociception: possible release of GABA.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

The role of 5HT3 in nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Antinociceptive effects of intrathecally administered 2-methylserotonin in developing rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

5-HT3 receptors modulate spinal nociceptive reflexes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Reversal of the antinociceptive effects of intrathecally administered serotonin in the rat by a selective 5-HT3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Serotonin and nociception

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Serotonin unmasks functional NK-2 receptors in vagal sensory neurones of the guinea-pig

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Morphine, 5-HT2 and 5-HT3 receptor antagonists reduce c-fos expression in the trigeminal nuclear complex following noxious chemical stimulation of the rat nasal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

5-HT1C receptor activation: a key step in the initiation of migraine?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Evidence of a central antinociceptive effect of paracetamol involving spinal 5HT3 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Response expectancies in placebo analgesia and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Placebos, drug effects, and study design: a clinician's guide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Possible mechanisms for ischemic colitis during alosetron therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2801%2900014-X

7 January 2021

10.1016/S0889-857X(01)00014-X

Identifiers

DOI

1 reference

31 July 2017

1 reference